KAS
OCUL icon

Kemnay Advisory Services’s Ocular Therapeutix OCUL Stock Holding History

Kemnay Advisory Services’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Buy
1,863
+188
+11% +$1.7K ﹤0.01% 779
2026
Q1 		$14.2K Buy
+1,675
New +$16K ﹤0.01% 877

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kemnay Advisory Services's OCUL Position: Q2 2026 in Review

Kemnay Advisory Services increased its Ocular Therapeutix (OCUL) stake by 11% in Q2 2026, buying an estimated $1.7K and bringing the position to 1,863 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Kemnay Advisory Services first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Kemnay Advisory Services held 1,863 shares of Ocular Therapeutix worth $18.3K as of Q2 2026.
  • Kemnay Advisory Services bought 188 Ocular Therapeutix shares in Q2 2026, an estimated $1.7K.
  • Ocular Therapeutix made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #779 holding.
  • Kemnay Advisory Services first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.